📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition. (2020)

First Author: Wu Z

Attributed to: Maximising patient benefit: Leeds’ Interdisciplinary approach to translation (CiC 2017) funded by UKRI

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acsmedchemlett.0c00186

PubMed Identifier: 32944138

Publication URI: http://europepmc.org/abstract/MED/32944138

Type: Journal Article/Review

Volume: 11

Parent Publication: ACS medicinal chemistry letters

Issue: 9

ISSN: 1948-5875